MML Investors Services LLC Has $5.83 Million Stake in Iqvia Holdings Inc (NYSE:IQV)

MML Investors Services LLC boosted its holdings in Iqvia Holdings Inc (NYSE:IQV) by 9.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,256 shares of the medical research company’s stock after purchasing an additional 3,129 shares during the quarter. MML Investors Services LLC’s holdings in Iqvia were worth $5,834,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Geode Capital Management LLC boosted its holdings in Iqvia by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock worth $247,087,000 after purchasing an additional 164,811 shares in the last quarter. Systematic Financial Management LP bought a new stake in Iqvia in the first quarter worth $3,310,000. Toronto Dominion Bank boosted its holdings in Iqvia by 15.1% in the first quarter. Toronto Dominion Bank now owns 111,876 shares of the medical research company’s stock worth $16,089,000 after purchasing an additional 14,690 shares in the last quarter. Trillium Asset Management LLC boosted its holdings in Iqvia by 1.0% in the first quarter. Trillium Asset Management LLC now owns 127,711 shares of the medical research company’s stock worth $18,371,000 after purchasing an additional 1,220 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its holdings in Iqvia by 12.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 207,762 shares of the medical research company’s stock worth $29,887,000 after purchasing an additional 22,560 shares in the last quarter. Institutional investors and hedge funds own 89.93% of the company’s stock.

IQV has been the subject of a number of recent research reports. Wells Fargo & Co upped their price objective on shares of Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Credit Suisse Group upped their price objective on shares of Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. William Blair reiterated an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. JPMorgan Chase & Co. boosted their target price on shares of Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Finally, Morgan Stanley boosted their target price on shares of Iqvia from $156.00 to $170.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 19th. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $162.08.

Iqvia stock traded up $0.12 on Thursday, reaching $150.35. 40,742 shares of the stock were exchanged, compared to its average volume of 1,245,012. The stock has a market cap of $29.75 billion, a PE ratio of 29.35, a PEG ratio of 1.85 and a beta of 0.90. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.72. Iqvia Holdings Inc has a twelve month low of $104.90 and a twelve month high of $164.13. The firm has a fifty day moving average price of $155.54 and a two-hundred day moving average price of $146.52.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.38 by $0.01. The firm had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.29 EPS. Equities analysts anticipate that Iqvia Holdings Inc will post 5.87 EPS for the current fiscal year.

In other news, insider Kevin C. Knightly sold 4,278 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $158.50, for a total transaction of $678,063.00. Following the completion of the transaction, the insider now owns 4,084 shares of the company’s stock, valued at $647,314. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,616,028 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $156.85, for a total transaction of $410,323,991.80. The disclosure for this sale can be found here. Insiders have sold 2,819,251 shares of company stock valued at $441,863,046 in the last ninety days. 6.00% of the stock is owned by company insiders.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: CD Ladder

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply